Here is an easy catalyst that doesn't involve AMBS

Here is an easy catalyst that doesn't involve AMBS receiving partnership money but which nevertheless would move the stock above .12 cents immediately: LYMPRO'S FIRST WORK ORDER to be used in a clinical trial.

AMBS has shown Lympro to the Alzheimer's world at the Conferences in July, and surely they've been in contact with AD pharmas since then making them aware of Lympro's December launch. Therefore, one would think we'd have nabbed at least one, if not two or three pharmas by now to give us a try at saving them clinical trial money?

Forget all our other catalysts, evidence that Lympro is being accepted by the Alzheimer's world would give Lympro and AMBS and Gerald the credibility they all so desperately need! I don't really care about how much money the first few pharmas pay us, the big revenue will come in time if Lympro is embraced by the industry. It wouldn't take too many work orders for the market to become convinced that LymPro is going to be huge.

If we don't have a single work order by the end of December, then 2015 is going to be slower than most of us hoped. If LymPro is hot and big pharma wants it....we should have AT LEAST one work order by year end. That would move us well above .12 cents all by itself!

Then, the Retinitis orphan, Eltoprazine 2b trial, and ESS and everything else AMBS has going.....will loom so much larger! Whether AMBS management is aware of it or not, the market doesn't really care about anything else we have until it sees signs of revenue from Lympro. We're riding on Lympro's back right now.